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ABSTRACT 
Background: Myocardial infarction (MI) is a leading cause of heart failure and death 
worldwide. Preservation of contractile function and protection against adverse changes in 
ventricular architecture (cardiac remodeling) are key factors to limiting progression of this 
condition to heart failure. Consequently, new therapeutic targets are urgently required to 
achieve this aim. Expression of the Runx1 transcription factor is increased in adult 
cardiomyocytes following MI; however, the functional role of Runx1 in the heart is unknown. 
Methods: To address this question, we have generated a novel tamoxifen-inducible 
cardiomyocyte-specific Runx1-deficient mouse. Mice were subjected to MI by means of 
coronary artery ligation. Cardiac remodeling and contractile function were assessed 
extensively at the whole heart, cardiomyocyte and molecular levels. 
Results: Runx1 deficient mice were protected against adverse cardiac remodeling post-MI, 
maintaining ventricular wall thickness and contractile function. Furthermore, these mice 
lacked eccentric hypertrophy and their cardiomyocytes exhibited markedly improved calcium 
handling. At the mechanistic level, these effects were achieved through increased 
phosphorylation of phospholamban by PKA and relief of sarcoplasmic reticulum calcium 
pump (SERCA) inhibition. Enhanced SERCA activity in Runx1 deficient mice increased 
sarcoplasmic reticulum calcium content and sarcoplasmic reticulum-mediated calcium 
release, preserving cardiomyocyte contraction post-MI.  
Conclusion: Our data identified Runx1 as a novel therapeutic target with translational 
potential to counteract the effects of adverse cardiac remodeling, thereby improving survival 
and quality of life among patients with MI. 
 
Key Words: myocardial infarction, myocytes, calcium, sarcoplasmic reticulum, remodeling    
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CLINICAL PERSPECTIVE 
 
 
What is new? 
• Our study provides new evidence that Runx1, a gene intensively studied in the 
cancer and blood research fields, has a critical role in cardiomyocytes following 
myocardial infarction (MI). 
• We provide conclusive evidence that increased Runx1 expression under pathological 
conditions leads to decreased cardiac contractile function. 
• Experiments performed utilizing a newly generated cardiomyocyte-specific Runx1 
deficient mouse reveal that reducing Runx1 function preserves myocardial 
contractility and prevents adverse cardiac remodeling post-MI. 
 
What are the clinical implications? 
• Our mechanistic data robustly demonstrate that Runx1 modulates cardiac 
sarcoplasmic reticulum (SR) calcium uptake and contractile function. 
• Reducing Runx1 function drives increased contractility post-MI, thereby preserving 
LV systolic function and preventing adverse cardiac remodeling.  
• Our study therefore importantly identifies Runx1 as a new target holding major 
promise for limiting the progression to h art failure among patients with MI by 
preventing adverse cardiac remodeling.   
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BACKGROUND 
Acute coronary artery blockage leading to prolonged ischemia and subsequent 
cardiomyocyte death (myocardial infarction; MI) initiates a reparative process in the heart 
that is associated with the generation of regional infarct tissue composed predominately of 
fibrillar collagens. The surviving cardiomyocytes undergo eccentric hypertrophy, a process 
characterized by cardiomyocyte elongation with reduced diameter and impaired calcium 
handling, in particular decreased sarcoplasmic reticulum (SR)-mediated calcium uptake1. 
These cellular changes are fundamental to adverse cardiac remodeling, which manifests 
clinically as left ventricular (LV) wall thinning, dilation and reduced contractility2. Together 
with neurohumoral activation, adverse cardiac remodeling post-MI leads to the clinical 
syndrome of systolic heart failure (HF), which despite optimized medical therapy is 
associated with extremely high mortality rates3. Novel therapeutic strategies to preserve LV 
contractile function and limit adverse cardiac remodeling are therefore urgently required to 
treat patients with MI and improve survival rates and quality of life. 
 
The Runx gene family (RUNX1, RUNX2 and RUNX3) encodes DNA-binding -subunits that 
partner core binding factor β (CBFβ) to form heterodim ric transcription factors4. RUNX 
proteins act as both activators and repressors of target genes in normal development and 
disease states4. To date, most research has focused on the role of RUNX1 in hematopoiesis 
owing to the frequent involvement of this gene in leukemic translocations4. By contrast, little 
was known about the role of Runx1 in the heart. This discrepancy is not surprising given that 
although Runx1 expression is reported in neonatal cardiomyocytes it decreases to minimal 
levels in adult cardiomyocytes5, 6. However, studies have demonstrated that Runx1 is re-
activated in cardiomyocytes of the border zone (BZ) region adjacent to the infarct in both 
patients with MI and experimental animal models5, 7. Whether activation of Runx1 in adult 
cardiomyocytes following MI is simply a marker of myocardial damage or actually plays a 
role in the progression of adverse cardiac remodeling is currently unknown. 
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 4 
We have now addressed this question by inducing MI in a mouse model where Runx1 has 
been specifically excised in cardiomyocytes. We report that these mice were protected 
against adverse cardiac remodeling following MI, with markedly preserved LV systolic 
function through improved SR-mediated calcium uptake. Re-activation of Runx1 following MI 
therefore plays a crucial role in excitation–contraction (EC) coupling and adverse cardiac 
remodeling and represents a new therapeutic target with the potential to limit progression to 
heart failure among patients with MI. 
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METHODS 
Detailed methods are provided in the Supplementary Supplemental Material. Requests by researchers to 
access the data, analytic methods, and study materials for the purposes of reproducing the 
results or replicating procedures can be made to the corresponding author who manages the 
information. The care and use of animals was in accordance with the UK Government 
Animals (Scientific Procedures) Act 1986 (ASPA). All animal procedures were approved by 
the University of Glasgow ethical review panel and licensed by the Home Office, UK (Project 
License Number 600/4503). 
 
Coronary artery ligation 
Mice aged 10–12 wk (25–30g) underwent thoracotomy and left anterior descending (LAD) 
coronary artery ligation (permanent/temporary) using standard approaches. 
 
Generation of cardiomyocyte specific Runx1 knock-out mice 
Runx1fl/fl mice described previously8, were crossed with mice expressing tamoxifen-inducible 
Cre recombinase (MerCreMe) under the control of the cardiac specific alpha-myosin heavy 
chain (αMHC)9 to produce the relevant test and control cohorts (Supplementary 
Supplemental Material). PCR of genomic DNA, RNA isolation, cDNA synthesis, real-time 
qPCR analysis and immunoblotting are detailed in the Supplementary Supplemental 
Material.  
 
Cardiac phenotyping 
Echocardiography M-mode measurements were performed before and after LAD ligation 
and pressure–v lume (PV) loop measurements recorded as a terminal procedure using the 
Scisense/Transonic small animal model PV system. 
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 6 
Histology 
Quantification of regional areas and infarct size was performed on picrosirius red/triphenyl 
tetrazolium chloride (TTC) stained histological sections using Image J and Adobe 
Photoshop. Cardiomyocyte size was assessed by AlexaFluor-594 conjugated wheat germ 
agglutinin (WGA; Invitrogen, UK) on adjacent sections. RNAscope using probes to 
specifically identify cardiomyocyte nuclei (pericentriolar material 1; PCM-1) and Runx1 was 
performed as detailed in the Supplementary Supplemental Material. For each heart, positive 
(PPIB and POLR2A) and negative controls (bacterial dapB) were run (Supplementary 
Supplemental Material Figure 1). 
 
Calcium measurements  
Cardiomyocytes were isolated as previously described10, loaded with a calcium–sensitive 
fluorophore (5.0mol/L Fura-4F AM, Invitrogen) and perfused during field–stimulation 
(1.0Hz, 2.0ms duration, stimulation voltage set to 1.5 x threshold). The Fura-4F fluorescence 
ratio (340/380nm excitation) was measured using a spinning wheel spectrophotometer 
(Cairn Research Ltd.; sampling rate of 5.0kHz) to measure the intra-cardiomyocyte [Ca2+]i. 
Cell-edge detection (IonOptix) was used to measure cell length. Data were analyzed offline 
as previously described11. Particular experiments utilized pretreatment (30min) and 
perfusion with the PKA inhibitor H89 (1mol/L; Tocris Biosciences, Bristol UK) as previously 
described12. 
 
Adenoviral overexpression of Runx1 in vitro 
Adenoviral vectors expressing either enhanced green fluorescent protein (GFP; Ad-GFP) or 
GFP and Runx1 in a bicistronic configuration (Ad-Runx1) were prepared and titered (see 
Supplementary Supplemental Material). Cardiomyocytes isolated from adult New Zealand 
white rabbits (3kg) were cultured and transduced at a multiplicity of infection (MOI) of 100 for 
24h.  
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 7 
 
Statistics  
Data were expressed as mean±SEM. Comparisons between MI and sham hearts were 
performed using the Student’s t test on raw data before normalization to percentage change. 
Comparisons between more than two groups were conducted on raw data using ANOVA. In 
cases where the two control groups were combined, statistics were performed on the pooled 
raw data of both control groups and compared with Runx1Δ/Δ mice using the Student’s t test. 
In experiments where multiple isolated cardiomyocyte observations (n) were obtained from 
each heart (N), we have firstly ensured normality of data distribution and then determined 
the differences between control and experimental mice using linear mixed modeling (IBM 
SPSS Statistics v22) as previously published13. 
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 8 
RESULTS 
 
Expression of Runx1 following MI 
Whilst Runx1 expression has previously been shown to increase at 3 wk post-MI it was 
unknown whether increased Runx1 expression occurred at a later time-point post-MI (e.g. 8 
wk post MI). Furthermore, temporal changes in regional Runx1 expression have not 
previously been investigated. Runx1 expression was therefore quantified in hearts taken 
from C57BL/6J mice with MI induced by permanent coronary artery ligation and compared 
with C57BL/6J mice that had a sham procedure but no coronary artery ligation. PV loop 
measurements confirmed C57BL/6J mice with MI had reduced systolic (Supplemental 
Material Figure 2A-C) and diastolic function (Supplemental Material Figure 2D&E) with a 
lower ejection fraction (Supplemental Material Figure 2F-H). 
 
Runx1 mRNA and protein levels 
The levels of Runx1 mRNA increased by 2.5 fold in whole hearts 4 wk post-MI relative to 4 
wk sham hearts (P<0.05; Supplemental Material Figure 2I). To determine the contribution of 
specific myocardial regions to the observed increase in Runx1 mRNA l vel, a separate 
cohort of sham and MI hearts were isolated and tissue isolated from four different regions 
(Supplemental Material Figure 2J). Runx1 mRNA levels analyzed using the relative 
quantification (RQ) method increased by 5.1 fold and 1.8 fold in the infarct (INF) and BZ 
regions of 4 wk post-MI hearts relative to the respective right ventricular (RV) region 
(P<0.05; Supplemental Material Figure 2K). No detectable change was noted in the Runx1 
mRNA levels in the LV region at 4 wk post-MI and no statistically significant regional 
differences were detected in the sham hearts (Supplemental Material Figure 2K).  
The levels of Runx1 protein changed in line with levels of Runx1 mRNA (Supplemental 
Material Figure 2L and M). Runx1 protein levels increased by 6.4 fold and 13.0 fold in the BZ 
and INF regions, respectively, relative to the LV region in 3 wk post-MI hearts (P<0.05).  
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 9 
The pattern of Runx1 mRNA expression was similar in 8 wk post-MI hearts, with an increase 
of 3.7 fold and 2.2 fold in the INF and BZ regions, respectively, relative to the corresponding 
RV region (P<0.05; Supplemental Material Figure 3). However, in contrast to 4 wk post-MI 
hearts, the Runx1 mRNA levels were increased by 2.7 fold in the LV region relative to the 
RV region (P<0.05) at the 8 wk time point (Supplemental Material Figure 3). 
All of the observed regional changes in Runx1 mRNA expression occurred in the absence of 
any such changes in the RV region of MI hearts relative to sham hearts. 
 
Expression of Runx1 in cardiomyocytes following MI 
We next delineated the spatial-temporal expression of Runx1 in cardiomyocytes from other 
cardiac cell types within different regions of the heart using RNAscope. Runx1 expression 
was found in 8-13% of cardiomyocytes and 5-7% of non-cardiomyocytes in the four regions 
(RV, LV and equivalent BZ and INF) of sham hearts (Figure 1A, B and C). Runx1 expression 
did not significantly differ from sham levels in the RV and LV regions at 1 and 14 day post-MI 
(Figure 1A, B and C). However, Runx1 expression significantly increased to 43% and 44% 
of cardiomyocytes within the BZ and INF region respectively at 1 day post MI; a time where 
whole heart contractile dysfunction was also first observ d (Figure 1A and B and 
Supplemental Material Figure 4). Furthermore, Runx1 expression significantly increased to 
59% and 47% of cardiomyocytes within the BZ and INF region respectively at 14 day post 
MI (Figure 1A and B). With regards to other cardiac cell types, Runx1 expression 
significantly increased to 14% of non-cardiomyocytes within the INF region at 1 day post MI 
(Figure 1A and C) and increased further to 35% and 26% of non-cardiomyocytes within the 
BZ and INF region respectively at 14 day post MI (Figure 1A and C). These data supported 
separate experiments which found an increased Runx1 level at 1 and 14 days post-MI in 
cardiomyocytes isolated from whole hearts and separated from other cell types as measured 
using rtqPCR data even though these data did not provide spatial resolution (Figure 1D). 
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 10 
Direct assessment of Runx1 function in cardiomyocytes.  
To directly determine the contribution of Runx1 in cardiomyocytes to reduced cardiac 
function, we generated cardiomyocyte-specific Runx1-deficient mice using Cre-LoxP-based 
gene targeting strategies (Supplemental Material and Supplementary Supplemental Material 
Figure 5)9. Three groups of mice were generated: Runx1Δ/Δ mice (αMHC-
MerCreMer:Runx1fl/fl); litter-mate Runx1fl/fl mice controlling for the insertion of the LoxP sites8 
and Runx1wt/wt mice controlling for insertion of the tamoxifen-inducible Cre recombinase 
(αMHC-MerCreMer:Runx1wt/wt)9. Cardiomyocyte-specific excision of Runx1 was induced in 
adult mice by a single i.p. injection of tamoxifen (40mg/Kg). PCR of genomic DNA, rtqPCR 
and western blot analysis was performed on isolated cardiomyocytes and confirmed 
successful deletion of the Runx1 gene following injection with tamoxifen (Supplementary 
Supplemental Material Figure 5).  
 
In vivo echocardiographic assessment of Runx1Δ/Δ mice post-MI 
In order to establish whether LV systolic function was altered in Runx1Δ/Δ mice post-MI we 
utilized M-mode echocardiography.   
 
Cardiac function 
MI was surgically induced in Runx1Δ/Δ, Runx1fl/fl and Runx1wt/wt mice 1 wk after tamoxifen 
injection to all mice. Echocardiography was performed before MI and every 2 wk post-MI to 
assess cardiac contractile function (Figure 2A). As expected, cardiac systolic function 
(assessed by fractional shortening) decreased in both groups of control mice (Runx1fl/fl and 
Runx1wt/wt) post-MI (Figure 2B). By contrast, Runx1Δ/Δ mice demonstrated a markedly 
preserved fractional shortening that was 158% of the control mice at 8 wk post-MI (39.5±0.7 
vs. 24.9±1.9%; P<0.05; Figure 2A and B). Runx1Δ/Δ mice undergoing a sham procedure 1 
wk post-tamoxifen injection demonstrated no change in fractional shortening over the 
equivalent 8 wk time course and were not significantly different from the Runx1Δ/Δ MI mice 
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 11 
until the 8 wk time point (Figure 2B). The improved fractional shortening in Runx1Δ/Δ mice 
post-MI was the culmination of substantially improved cardiac contraction as evidenced by 
the smaller LV internal diameter measured at systole (LVIDs; Figure 2A and C), which was 
77% of the two control groups post-MI (2.5±0.2 vs. 3.3±0.1mm; P<0.05). Runx1Δ/Δ mice 
undergoing a sham procedure post-tamoxifen administration demonstrated no change in 
LVIDs over the equivalent 8 wk time course. The LVID measured at diastole (LVIDd) within 
the BZ region indicated that the hearts of both control and Runx1Δ/Δ mice post-MI dilated at 
this level of the myocardium albeit to a lesser degree in Runx1Δ/Δ mice (Figure 2D). 
 
Cardiac structure 
As expected, LV posterior wall thickness during systole (LVPWs) measured at the level of 
the BZ of control mice (Runx1fl/fl and Runx1wt/wt) thinned after the 2 wk post-MI time point due 
to the cardiac remodeling process (Figure 2E). By contrast, Runx1Δ/Δ mice displayed 
preserved wall thickness that was 164% of control mice (Runx1fl/fl and Runx1wt/wt) at 8 wk 
post-MI (2.07±0.14 vs. 1.27±0.06mm; P<0.05; Figure 2E). Runx1Δ/Δ mice undergoing a 
sham procedure post-MI demonstrated no change in LVPWs over the quivalent 8 wk time 
course. The wall-thickness data were confirmed at diastole 8 wk post-MI (Figure 2F). 
 
These data were confirmed in: (i) a separate blinded study (Supplementary Supplemental 
Material Figure 6A-E) where the operator was blinded to the animals undergoing surgery, 
echocardiography and analysis before MI and at 2 wk post-MI and (ii) at earlier time points 
at and before 1 wk post-MI (Supplementary Supplemental Material Figure 7). 
 
In vivo ventricular luminal volumes and ejection fraction in Runx1Δ/Δ mice 2 wk post-MI 
LV ventricular luminal volume of the Runx1Δ/Δ and control mice was assessed in vivo at 2 wk 
post-MI using pressure volume (PV) loops (Figure 2G). The end diastolic volume (EDV) in 
the Runx1Δ/Δ mice was reduced to 82% of that in the control mice (Runx1fl/fl and Runx1wt/wt), 
indicating a reduction in LV dilation (36.3±3.00 vs. 44.5±2.47L; P<0.05; Figure 2G and H). 
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 12 
The end systolic volume (ESV) in Runx1Δ/Δ mice was reduced to 54% of that of the control 
mice, indicating a greater level of emptying of LV blood volume (12.9±2.98 vs. 23.7±2.51L; 
P<0.05; Figure 2G and I). This leftward shift in the PV loop in the Runx1Δ/Δ mice resulted in 
an ejection fraction (EF) that was 138% of the control mice (66.3±5.69 vs. 48.0%±3.18%; 
P<0.05; Figure 2G and J). 
 
Histological assessment of Runx1Δ/Δ mice 8 wk post-MI 
Heart structure 
We next investigated whether altered whole heart structure contributed to the preserved 
cardiac performance of Runx1Δ/Δ mice post-MI. Analysis of the different regions of the heart 
(Figure 3A) using picrosirius red staining of serial sections of hearts from Runx1Δ/Δ mice 8 wk 
post-MI showed that the mean two-dimensional whole heart area (RV+SEP+LV+INF) was 
112% of control mice (Runx1fl/fl and Runx1wt/wt) post-MI (37.4±1.4 vs. 33.5±0.6mm2; P<0.05; 
Figure 3B). This increase in heart area was associated with the LV free wall (Figure 3A; 
dotted area), which in Runx1Δ/Δ mice post-MI was 127% of the control mice post-MI 
(11.0±0.8 vs. 8.7±0.4mm2; P<0.05; Figure 3C). No change was detected in the RV wall area 
in Runx1Δ/Δ mice post-MI (Figure 3D) and therefore further investigation focused on the 
structure of the LV. 
 
LV wall thickness (measured at the level of the BZ; Figure 3A; arrows) in Runx1Δ/Δ mice 
post-MI was 127% of control mice post-MI (2.07±0.2 vs. 1.63±0.1mm; P<0.05; Figure 3E), a 
finding that supported the echocardiographic data (Figure 2E). No change was detected in 
the septal-wall thickness in Runx1Δ/Δ mice post-MI (Figure 3F) or overall heart weight (Figure 
3G). Infarct thickness and fibrosis (Figure 3H&I) was not different in Runx1Δ/Δ mice post-MI 
versus control mice post-MI. Furthermore, infarct size (32.31.5% vs. 32.73.1 vs. 31.95% 
of LV; Runx1Δ/Δ (N=5) vs. Runx1wt/wt  (N=7) vs. Runx1fl/fl (N=5); P>0.05; Figure 3J) at 8 wks 
post-MI (and the earlier time point of 24 h post-MI; Supplementary Supplemental Material 
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Figure 8A and B) was not different in Runx1Δ/Δ versus control mice, and therefore did not 
explain the preserved LV function observed in vivo (Figure 2B).  
 
Cardiomyocyte size 
To investigate why LV free wall thickness was preserved in Runx1Δ/Δ mice 8 wk post MI 
relative to the wall thinning observed in control mice post-MI (Figures 2E and F), the 
cardiomyocyte size in Runx1Δ/Δ mice 8 wk post MI was determined using wheat germ 
agglutinin staining (WGA). As expected, LV cardiomyocytes from control Runx1fl/fl and 
Runx1wt/wt mice 8 wk post-MI exhibited significant cell lengthening to 121% and 118% of 
Runx1Δ/Δ sham mice (111.7±3.8 vs. 108.8±3.7 vs. 92.53±1.04m; P<0.05; Figure 3K and L). 
However, cardiomyocyte elongation was absent in Runx1Δ/Δ mice at 8 wk post-MI (Figure 3K 
and L). An equivalent absence of cardiomyocyte lengthening was also observed in septal 
cardiomyocytes (Figure 3M). LV cardiomyocytes from control Runx1fl/fl and Runx1wt/wt mice 8 
wk post-MI exhibited a significant decrease in cell diameter to 86% and 85% of Runx1Δ/Δ 
sham mice (15.91±0.83 vs. 15.88±0.75 vs. 18.86±0.37m; P<0.05; Figure 3N and O). 
However, cardiomyocyte cell diameter did not decrease in Runx1Δ/Δ mice 8 wk post-MI 
(Figure 3O). LV cardiomyocytes from control Runx1fl/fl and Runx1wt/wt mice 8 wk post-MI 
exhibited a significant decrease in cardiomyocyte cross-sectional area to 79% and 76% of 
Runx1Δ/Δ sham mice (350.6±23.9 vs. 338.2±22.6 vs. 440.0±11.5m; P<0.05; Figure 3N and 
P). However, cardiomyocyte cell cross-sectional area did not decrease in Runx1Δ/Δ mice 8 
wk post-MI (Figure 3P). No change in septal cardiomyocyte diameter was observed at 8 wk 
post-MI in any group (Figure 3Q). 
 
Calcium transients in Runx1Δ/Δ mice 2 wk post-MI 
Although increased fractional shortening paralleled increased wall thickness in Runx1Δ/Δ 
mice at 8 wk post-MI (Figure 2B and E), we noted that wall thickness was not significantly 
different between the three groups at 2 wk post-MI. However, Runx1Δ/Δ mice still exhibited 
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greater fractional shortening at this time point than was observed for the two control groups. 
To investigate this dichotomy, we isolated cardiomyocytes from hearts at 2 wk post-MI to 
characterize calcium handling. This was achieved by measuring the intracellular calcium 
concentration ([Ca2+]i), focusing on electrically induced SR-mediated calcium release 
(calcium transients) into the cytosol, which predominately determines the force of 
contraction. 
 
Cardiomyocytes isolated at 2 wk post-MI were stimulated at 1.0 Hz to elicit calcium 
transients and cell shortening (Figure 4A-C). The calcium transient peak (systolic [Ca2+]i) in 
Runx1Δ/Δ mice was 117% and 122% of the control (Runx1fl/fl and Runx1wt/wt) mice 
(582.8±36.1 vs. 497.4±31.3 nM vs. 477.0±24.5nM [Ca2+]i; P<0.05; Figure 4B and D). The 
calcium transient minimum (diastolic [Ca2+]i) in Runx1Δ/Δ mice was 92% and 89% of the 
control (Runx1fl/fl and Runx1wt/wt) mice (137.8±4.5 vs. 149.8±6.3 vs. 155.1±6.8nM [Ca2+]i; 
P<0.05; Figure 4B and E). The changes in peak and minimum [Ca2+]i of Runx1Δ/Δ mice 
resulted in a calcium transient amplitude which was 128% and 138% of the control (Runx1fl/fl 
and Runx1wt/wt) mice (445.0±34.3 vs. 347.5±29.0 vs. 321.9±20.7nM [Ca2+]i; P<0.05; Figure 
4B and F). Furthermore, the time constant of calcium transient decay in the Runx1Δ/Δ mice 
was 65% and 55% of the control (Runx1fl/fl and Runx1wt/wt) mice (0.074±0.007 vs. 
0.114±0.018 vs. 0.134±0.020s; P<0.05; Figure 4B and G), suggesting an increased rate of 
removal of calcium from the cytosol. 
 
The increased calcium transient amplitude in Runx1Δ/Δ mice post-MI occurred in the absence 
of any significant changes in calcium entry or action potential duration (as measured 
indirectly using the QT interval on the electrocardiogram or directly using voltage 
measurements on isolated cardiomyocytes at 2 wk post-MI) (Supplementary Supplemental 
Material Figure 9). 
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Caffeine-induced calcium transients and cell shortening 
We hypothesized that the lowered time constant of decay detected in the Runx1Δ/Δ mice 2 
wk post-MI might reflect either increased SR calcium uptake via SERCA or extrusion from 
the cell via the sodium calcium exchanger (NCX). To address this issue, we applied a rapid 
bolus of 10mM caffeine at the end of the protocol to release all of the calcium from the SR 
into the cytosol. This approach enabled assessment of SR calcium content. 
 
The SR calcium content of the Runx1Δ/Δ mice was 135% and 118% of the control Runx1fl/fl 
and Runx1wt/wt mice, respectively (842.8±47.2 vs. 624.3±42.2 vs. 712.6±40.0nM [Ca2+]i; 
P<0.05; Figure 4H). SERCA-mediated calcium uptake is bypassed during application of 
10mM caffeine and cytosolic calcium removal occurs predominately via NCX. The activity of 
NCX, as assessed by the time constant of caffeine-induced calcium transient decay, was not 
different between the three groups (Figure 4I). 
 
The increased SR calcium content observed in Runx1Δ/Δ mice might reflect enhanced 
SERCA activity (KSERCA). Therefore, we measured the rate constant of decay of the caffeine-
induced calcium transient (which includes sarcolemmal fflux but not SR calcium uptake) 
and subtracted this value from that of the lectrically stimulated calcium transient (which 
includes both SR calcium uptake and sarcolemmal efflux)14, 15. The KSERCA of the Runx1Δ/Δ 
mice was 148% and 160% of control Runx1fl/fl and Runx1wt/wt mice (14.4±1.4 vs. 9.7±1.8 vs. 
9.0±1.2s-1; P<0.05; Figure 4J). To corroborate that the increased calcium transient amplitude 
of Runx1Δ/Δ mice resulted in increased cell shortening, we performed edge-detection 
shortening measurements (Figure 4C). Cardiomyocyte shortening in Runx1Δ/Δ mice 2 wk 
post-MI was 156% and 203% of the control Runx1fl/fl and Runx1wt/wt mice (7.5±0.9 vs. 
4.8±0.6 vs. 3.7±0.4% of diastolic length; P<0.05; Figure 4C and K). 
 
 
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
 16 
Effect of overexpressing Runx1 on calcium transient amplitude and SR calcium content in 
normal cardiomyocytes 
To further support the novel link between Runx1 and calcium handling in isolated 
cardiomyocytes, we performed a gain-of-function study by overexpressing Runx1 via 
adenoviral-mediated gene transfer (Ad-Runx1) in isolated adult cardiomyocytes from normal 
hearts. The calcium transient amplitude in Ad-Runx1-transduced cardiomyocytes was 53% 
of cardiomyocytes transduced with the control adenoviral vector expressing green 
fluorescent protein (Ad-GFP) (70.5±8.3 vs. 133.4±30.7nM [Ca2+]i; P<0.05; Figure 4L and M). 
SR calcium content in cardiomyocytes overexpressing Runx1 was 60% of the control 
cardiomyocytes (388.8±60.3 vs. 651.8±84.4nM [Ca2+]i; P<0.05; Figure 4N). 
 
Expression of calcium handling proteins in Runx1Δ/Δ mice 2 wk post-MI 
To investigate the mechanism by which SERCA activity is increased, we quantified the 
expression and phosphorylation levels of key calcium handling proteins involved in the 
control of SERCA-mediated calcium uptake in isolated cardiomyocytes 2 wk post-MI.  
 
Levels of phospholamban (PLB), an inhibitory protein that regulates SERCA activity, were 
not significantly altered in the Runx1Δ/Δ mice (Figure 5A and B). By contrast, phosphorylation 
of PLB (which relieves SERCA inhibition and improves cardiac contractility) at the PKA-
target residue Ser16 [P-PLB (Ser16)] was 331% of the control mice (Runx1wt/wt and Runx1fl/fl) 
(331.2±94.5 vs. 100±35.6% change; P<0.05; Figure 5A and C). 
 
Decreased levels of PKC indirectly enable enhanced phosphorylation of PLB and increase 
cardiac contractility16; however, no between-group differences were detected in the levels of 
PKC (Figure 5D and E). Phosphorylation of PLB at the CaMKII-target residue threonine-17 
([P-PLB (Thr17)] in Runx1Δ/Δ mice was 175% of the control mice (Runx1wt/wt and Runx1fl/fl) 
(175.0±22.9 vs. 100±8.2% change; P<0.05; Figure 5D and F). A possible regulator of 
phosphorylation of PLB is protein phosphatase 1 (PP1), which dephosphorylates PLB16. We 
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found that expression of PP1 in Runx1Δ/Δ mice was decreased to 28% of the control mice 
(Runx1wt/wt and Runx1fl/fl) post-MI (27.6±19.4 vs. 100±21.3% change; P<0.05; Figure 5G and 
H). 
 
To confirm that the increased SERCA activity, SR calcium content and calcium transient 
amplitude observed in Runx1Δ/Δ mice 2 wk post-MI (Figure 4) were PKA-mediated; we 
investigated the effect of the PKA inhibitor (H89) on calcium handling. Addition of H89 
completely blocked enhancement of all three parameters in the Runx1Δ/Δ mice relative to the 
control Runx1wt/wt and Runx1fl/fl mice (Figure 5I–K). 
 
Cardiac contractility in Runx1Δ/Δ mice after ischemia with reperfusion 
Reperfusion of a blocked coronary artery limits cell death following MI; this effect can be 
achieved clinically via percutaneous coronary intervention. We therefore tested whether 
Runx1Δ/Δ mice also maintain a preserved LV contractile function in an additional clinically 
relevant model of ischemia with reperfusion (I/R). 
 
The left anterior descending coronary artery was temporarily ligated in vivo for 45min 
followed by reperfusion and the Runx1Δ/Δ mice recovered for 8 wk. Fractional shortening was 
assessed using echocardiography before MI and weekly after the induction of MI with 
reperfusion. As expected, fractional shortening decreased in control Runx1fl/fl mice after 
reperfusion (Figure 6A and B). By contrast, Runx1Δ/Δ mice demonstrated markedly 
preserved fractional shortening, which was 154% of control Runx1fl/fl mice at 8 wk post-
reperfusion (42.7±1.5 vs. 27.7±2.13%; P<0.05; Figure 6A and B). As with the animal model 
of permanent coronary artery ligation, infarct size at 8 wks post-reperfusion (and the earlier 
time point of 24 h post-reperfusion) was not different in Runx1Δ/Δ versus control mice (Figure 
6C and Supplemental Material Figure 8C and D).  
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DISCUSSION 
Runx1 has been most intensively studied in the hematopoietic system because its function is 
frequently corrupted in different subtypes of leukemia. Although it is known to have a role in 
lineage differentiation and tissue function in a range of other systems there is almost no 
information relating to its role in adult cardiomyocytes other than the observation that it can 
be reactivated following myocardial insult5, 7. Our novel study addressed a vital question; 
namely, is increased expression of RUNX1 post-MI merely a marker of ischemic damage or 
does it play a functional role in adult cardiomyocytes following MI? We provide new evidence 
that Runx1 has an important role in cardiomyocytes following MI. Reducing Runx1 function 
preserved cardiac contractility and prevented adverse cardiac remodeling, which suggests 
that targeting the actions of this gene could have important implications for patient survival 
post-MI. Importantly, this research transcends discipline boundaries as it not only widens the 
importance of Runx1 to other fields of medicine but also describes a novel function for this 
gene. 
 
Our results provide the first detailed quantification of regional Runx1 expression in mouse 
heart tissue after myocardial infarction. At 4 wk post-MI, Runx1 mRNA was increased within 
the BZ myocardium and INF region which was sustained until at least 8 wk post-MI, at which 
time point Runx1 expression also increased within the remote LV myocardium. This is 
important given that changes in Runx1 expression at the mRNA and protein level are not 
restricted to rodent MI models but also occur in patients with MI5, 7. In separate experiments, 
we were able to demonstrate that Runx1 expression is increased within the BZ and INF 
region post-MI within the contractile elements of the heart i.e. the cardiomyocytes, as early 
as 1 to 14 days post-MI (Figure 1).  
 
To determine the specific contribution of Runx1 in cardiomyocytes to reduced cardiac 
contractility, we generated a new tamoxifen-inducible cardiomyocyte-specific Runx1 
deficient mouse with the hypothesis that these mice would demonstrate improved cardiac 
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function. Induction of MI in control transgenic mice led to the expected LV wall thinning, 
cardiac dilation and reduced contractility 8 wk post-MI. However, all of these adverse cardiac 
remodeling parameters were absent or reduced in Runx1Δ/Δ mice at this time point. One 
possible explanation for the observed preservation of systolic function could have been a 
reduction in the infarct size of Runx1Δ/Δ mice given that infarct size correlates with systolic 
function17. However, Runx1Δ/Δ mice exhibited preservation of geometric shape and 
contractility post-MI, with no difference in infarct size (at both early and late time points) or 
fibrosis versus the control mice. 
 
To establish the mechanism underlying these notable findings, we first investigated 
cardiomyocyte size. Control mice demonstrated the expected cardiomyocyte lengthening 
and thinning (eccentric hypertrophy) at 8 wk post-MI1. However, these changes were absent 
in Runx1Δ/Δ mice. Such protection against eccentric hypertrophy at 8 wk post-MI seems 
highly likely to have afforded Runx1Δ/Δ mice protection from ventricular dilation and thinning, 
ultimately leading to preserved contractility. Nevertheless, at 2 wk post-MI, the wall thickness 
in Runx1Δ/Δ mice was comparable to that of control mice (as wall thinning in control mice had 
not yet begun) but contractile function was still dramatically improved. This finding indicated 
that prevention of wall thinning and dilation could not fully explain the preserved contractile 
function observed at 2 wk post-MI. 
 
The above dichotomy led us to investigate c lcium handling in cardiomyocytes isolated from 
Runx1Δ/Δ mice 2 wk post-MI, i  particular electrically stimulated calcium release (the calcium 
transient) from the intra-cardiomyocyte calcium store (the SR) and subsequent cell 
shortening. Patients and animal models with MI typically exhibit calcium transients with lower 
amplitude and a slower rate of decline than control/healthy cardiomyocytes, an observation 
largely attributed to reduced SR-mediated calcium uptake via SERCA15. Runx1Δ/Δ mice 
exhibited increased calcium transient amplitude and reduced time constant of decline post-
MI compared to control mice post-MI, resulting in an increase in cell shortening. The 
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accompanying higher SR calcium content observed in Runx1Δ/Δ mice post-MI can explain 
the enhanced calcium transient amplitude18 since equalizing the SR calcium content with 
H89 resulted in a calcium transient equivalent to control.   
 
Analysis of the caffeine-induced calcium transient found no detectable change in NCX 
activity in Runx1Δ/Δ mice post-MI as compared to control mice post-MI. However, enhanced 
SR-mediated calcium uptake via SERCA was observed in the Runx1Δ/Δ mice. SERCA 
activity is a major determinant of the SR calcium content. Furthermore, this pump is 
regulated predominately by the inhibitory protein phospholamban (PLB). Although 
expression of PLB was not altered in Runx1Δ/Δ mice post-MI, we explored some of the 
proteins that regulate PLB activity16.  
 
PLB-mediated inhibition of SERCA is balanced by phosphorylation by PKA and CaMKII 
(which relieves SERCA inhibition) and dephosphorylation by PP1 (which returns PLB to its 
inhibitory state16). We found that ventricular cardiomyocytes from Runx1Δ/Δ mice exhibited 
increased PKA-mediated phosphorylation of PLB possibly as a result of reduced levels of 
PP1. These mechanistic data suggest that PLB phosphorylation stimulates SERCA activity 
in Runx1Δ/Δ mice post-MI, and leads to an increased SR calcium content, which in turn 
increases electrically induced SR-mediated calcium release and doubles cardiomyocyte 
contraction. Our proposed mechanism was supported by complete blockage of the 
enhanced calcium transient in cardiomyocytes from Runx1Δ/Δ mice 2 wk post-MI by inhibition 
of PKA. The enhanced rate of removal of calcium from the cytosol following increased 
SERCA activity is sufficient to reduce the end diastolic [Ca2+]i, which not only improves 
whole heart relaxation but may also limit the stimulation of hypertrophic factors1.  
 
Previous studies strongly support our proposed mechanism that the effect of Runx1 on SR 
function is a major contributor to the beneficial effects observed in Runx1Δ/Δ mice post-MI. 
Decreased SR function has been demonstrated among patients with HF15 and enhanced 
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SR-mediated calcium cycling markedly preserved contractility, reduced adverse cardiac 
remodeling and delayed progression to heart failure at levels not dissimilar from those 
observed in the current study16, 19.  
 
The key findings of our study will likely initiate further research into the beneficial effects of 
decreasing Runx1 expression in alternative animal models of cardiac disease. As testament 
to this goal, we found that Runx1Δ/Δ mice are protected from adverse cardiac remodeling in a 
separate clinically relevant surgical model. In this model, the blocked coronary artery was 
subsequently unblocked after a period of ischemia, as would be the case for patients 
undergoing percutaneous coronary intervention. These additional data further support our 
study and the translational potential of this new target.  
 
Although our strategy did not result in inactivation of the Runx1 gene in all ca diomyocytes, 
we postulate that cardiac function improves when only a subset of cardi myocytes benefits 
from better Ca2+ handling after inactivation of Runx1. Since it is more feasible in a clinical 
setting to suppress genes in a subset of cardiomyocytes rather than in all cells, we think 
Runx1, or targets showing a similar potency, are particularly attractive for therapeutic 
interventions. 
 
In conclusion, we have demonstrated for the first time that Runx1 modulates cardiac SR 
calcium uptake and contractile function. Reducing Runx1 function drives increased 
contractility post-MI, thereby preserving LV systolic function and preventing adverse cardiac 
remodeling. Clinical studies clearly demonstrate that preserving cardiac contractility and 
protecting against adverse cardiac remodeling are key factors to limiting progression from MI 
to heart failure2. Identification of a new therapeutic target that achieves this objective is 
urgently required. To this end, we envisage that Runx1 will be exploited in future basic and 
translational studies to limit progression of patients with MI to heart failure, thereby 
improving survival rates and quality of life.  
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FIGURE LEGENDS 
Figure 1. Runx1 expression in WT C57BL/6 mice post-MI. (A) Typical images of regional 
heart sections with RNA in situ hybridization (using RNAscope®). Regions examined were 
right ventricle (RV), left ventricle (LV), border zone (BZ) and infarct (INF) in 1 day (middle; 
n=3) and 14 day (bottom; n=3) post-MI and equivalent regions in sham hearts (top; n=5). 
Probes for Runx1 (pink) and PCM-1 (cardiomyocyte specific; brown) were used; colored 
punctate dots represent positive staining (arrows). Scale bar (10m); magnified insert image 
(5m). (B) Mean quantification of cardiomyocytes (PCM-1+) and (C) non-cardiomyocytes 
PCM-1-) with Runx1 positive staining as a % of the total number of cardiomyocytes or non-
cardiomyocytes respectively (*P<0.05, 1 day post-MI vs. sham; #P<0.05, 14 day post-MI vs. 
sham - Student’s t-test). (D) Runx1 expression as measured by rtPCR in cardiomyocytes 
isolated from whole sham (n=17) and 1 day (n=8), 7 day (n=6) and 14 d y (n=3) post-MI 
hearts (ANOVA). Stock (C57BL/6J; n=4) mice were included to show that there was no 
detectable difference with sham hearts (ANOVA).  
 
Figure 2. Cardiac function in Runx1Δ/Δ mice. (A) Echocardiography 
(scale:x=0.1s;y=2mm). (B) 8 wk echocardiographic data for fractional shortening (FS) and 
(C) LV internal diameter (LVID) at systole (LVIDs), (D) LVID at diastole (LVIDd), (E) LV 
posterior wall thickness at systole (LVPWs) and (F) LVPW thickness at diastole (LVPWd). 
(Runx1fl/fl MI and Runx1wt/wt MI combined [n=11], Runx1Δ/Δ MI [n=9] and Runx1Δ/Δ sham 
[n=5]), (ANOVA). #P<0.05=Runx1Δ/Δ MI mice versus Runx1Δ/Δ sham mice 
*P<0.05=Runx1Δ/Δ MI mice versus control Runx1fl/fl MI and Runx1wt/wt MI mice combined. (G) 
Pressure–volume (PV) loops of Runx1wt/wt and Runx1Δ/Δ 2 wk post-MI. (H) Mean PV data 2 
wk post-MI End diastolic volume (EDV), (I) End systolic volume (ESV) and (J) Ejection 
fraction (EF) (Runx1fl/fl MI and Runx1wt/wt MI combined [n=11], Runx1Δ/Δ MI [n=8]), *P<0.05 
Student’s t-test. 
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Figure 3. Runx1Δ/Δ mice cardiac structure 8 wk post-MI. (A) Picrosirius red stained hearts 
(BZ,border zone; LV,left ventricle; INF,infarct; RV,right ventricle; SEP,septum; scale: 1mm). 
Mean (B) area of whole heart (all regions), (C) LV, (D) RV and (E) LV wall thickness at BZ 
region, (F) septum wall thickness at BZ region level, (G) heart weight to body weight ratio, 
(H) infarct thickness, (I) LV fibrosis and (J) infarct size (Runx1fl/fl MI and Runx1wt/wt MI 
combined [n=12], Runx1Δ/Δ MI [n=5]; *P<0.05), Student’s t-test. (K) Wheat germ agglutinin 
(WGA) staining of LV cardiomyocytes (longitudinal) of Runx1fl/fl MI (top) and Runx1Δ/Δ 
(bottom) post-MI (scale bar:25mm). (L) Mean LV cardiomyocyte length (Runx1Δ/Δ sham 
[n=55 cardiomyocytes,n=3 hearts], Runx1fl/fl MI [n=122 cardiomyocytes,n=6 hearts], 
Runx1wt/wt MI [n=109 cardiomyocytes from n=6 hearts], Runx1Δ/Δ MI [n=102 
cardiomyocytes,n=6 hearts]), *P<0.05 linear mixed modelling. (M) Mean SEP cardiomyocyte 
length (Runx1Δ/Δ sham [n=29 cardiomyocytes,n=3 hearts], Runx1fl/fl MI [n=82 
cardiomyocytes,n=6 hearts], Runx1wt/wt MI [n=84 cardiomyocytes,n=6 hearts], Runx1Δ/Δ MI 
[n=64 cardiomyocytes,n=6 hearts]. (N) WGA staining of LV cardiomyocytes (transverse) of 
Runx1wt/wt MI (Left) and Runx1Δ/Δ MI (Right) (scale bar:25mm). (O) Mean LV cardiomyocyte 
diameter (Runx1Δ/Δ sham [n=449 cardiomyocytes,n=3 hearts), Runx1fl/fl MI [n=811 
cardiomyocytes,n=6 hearts], Runx1wt/wt MI [n=897 cardiomyocytes,n=6 hearts], Runx1Δ/Δ MI 
[n=878 cardiomyocytes,n=6 hearts]). (P) Mean LV cardiomyocyte cross sectional area 
(Runx1Δ/Δ sham [n=403 cardiomyocytes,n=3 hearts), Runx1fl/fl MI [n=714 
cardiomyocytes,n=6 hearts], Runx1wt/wt MI [n=785 cardiomyocytes,n=6 hearts], Runx1Δ/Δ MI 
[n=699 cardiomyocytes,n=6 hearts]). (Q) Me n SEP cardiomyocyte diameter (Runx1Δ/Δ 
sham [n=238 cardiomyocytes,n=3 hearts], Runx1fl/fl MI [n=465 cardiomyocytes,n=6 hearts], 
Runx1wt/wt MI [n=454 car iomyocytes,n=6 hearts], Runx1Δ/Δ MI [n=452 cardiomyocytes,n=6 
hearts]), *P<0.05 linear mixed modelling. 
 
Figure 4. Excitation–contraction coupling in Runx1Δ/Δ mice 2 wk post-MI. (A) Protocol 
(B) Typical calcium (Ca2+) transients and (C) cell shortening. Mean Ca2+ transient: (D) peak, 
(E) minimum and (F) amplitude (Runx1fl/fl MI [n=25 cardiomyocytes,n=3 hearts], Runx1wt/wt 
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MI [n=28 cardiomyocytes,n=4 hearts], Runx1Δ/Δ MI [n=28 cardiomyocytes,n=3 hearts]; 
*P<0.05 Runx1Δ/Δ MI vs. Runx1fl/fl MI and Runx1wt/wt MI combined, linear mixed modelling). 
(G) Mean time constant of Ca2+ transient decay. (H) Mean caffeine-induced Ca2+ transient 
amplitude. (I) Mean time constant of decay for caffeine-induced Ca2+ transient amplitude. (J) 
Mean sarco–endoplasmic reticulum calcium transport ATPase (SERCA) activity. (K) Mean 
fractional shortening (Runx1fl/fl MI [n=27 cardiomyocytes,n=3 hearts], Runx1wt/wt MI [n=27 
cardiomyocytes,n=4 hearts], Runx1Δ/Δ MI [n=23 cardiomyocytes,n=3 hearts]). (L) Ca2+ 
transients from cardiomyocytes transduced with Ad-GFP or Ad-Runx1. Mean: (M) Ca2+ 
transient peak; Ad-GFP (n=16 cardiomyocytes,n=6 hearts) and Ad-Runx1 (n=22 
cardiomyocytes,n=6 hearts), *P<0.05 linear mixed modelling (N) Caffeine-induced Ca2+ 
transient amplitude; Ad-GFP (n=13 cardiomyocytes,n=6 hearts) and Ad-Runx1 (n=19 
cardiomyocytes,n=6  hearts), *P<0.05 linear mixed modelling. 
 
Figure 5. Phospholamban regulation in isolated cardiomyocytes fr m Runx1Δ/Δ mice 2 
wk post-MI. (A) Western blot of phospholamban (PLB), phosphorylation of PLB at serine-16 
[P-PLB (Ser16)] and pan-actin loading control. Percentage change in protein for (B) PLB 
and (C) P-PLB (Ser16/total PLB) (Runx1Δ/Δ MI [n=5 hearts] versus Runx1wt/wt and Runx1fl/fl 
MI [n=5 hearts]), *P<0.05 Student’s t-test. (D) Western blot of PKC, PLB, and PLB 
phosphorylation at threonine-17 (P-PLB (Thr17)). Percentage change in protein for (E) PKC 
and (F) P-PLB (Thr17/total PLB) (Runx1Δ/Δ MI [n=5 hearts] versus Runx1wt/wt MI and Runx1fl/fl 
MI [n=9 hearts]), *P<0.05 Student’s t-test. (G) Western blot of protein phosphatase 1 (PP1). 
(H) Percentage change in PP1 (Runx1Δ/Δ MI [n=5 hearts] versus Runx1wt/wt MI and Runx1fl/fl 
MI [n=9 hearts]). (I, J, K) Mean SERCA activity, caffeine–induced calcium transient 
amplitude and calcium transient amplitude data from Figure 4 compared to mean data 
obtained from 2 wk post-MI isolated cardiomyocytes with H89 (hatched white column; 
Runx1wt/wt MI and Runx1fl/fl MI+H89 [n=16 cardiomyocytes,3 hearts] and hatched red column; 
Runx1Δ/Δ MI+H89 [n=15 cardiomyocytes, 3 hearts]), *P<0.05 Student’s t-test.  
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
 29 
 
Figure 6. Runx1Δ/Δ mice after ischemia with reperfusion (I/R). (A) Echocardiographic 
images (scale:x=0.1s;y=2mm). (B) Mean echocardiographic fractional shortening data of 
Runx1fl/fl I/R (n=9) and Runx1Δ/Δ I/R (n=8) [*P<0.05], Student’s t-test. (C) Mean infarct size 
(Runx1fl/fl I/R [n=9] and Runx1Δ/Δ I/R [n=7]), Student’s t-test.  
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